PMS-Fampridine 10 mg Tablets Recalled Over Foreign Particles: Health Canada

Health Canada has posted a Type II health product recall for one lot of PMS-FAMPRIDINE 10 mg tablets, made by Pharmascience Inc., because the affected lot may contain foreign material particles. The notice was published on September 28, 2026, under identification number RA-82684.

The recall is confined to a single lot and covers distribution across seven Canadian provinces. Health Canada lists the depth of the recall as retailers. Consumers who take this medication are being told to check their supply and speak with a healthcare provider before making any changes to their treatment.

Regulatory Response

Health Canada published the recall through its Recalls and Safety Alerts portal, classifying it as a Type II health product recall in the Health products – Drugs category. The issue is categorized as contamination. The notice is addressed to the general public, healthcare professionals and industry.

The alert names Pharmascience Inc., based at 6111 Royalmount Ave. in Montreal, Quebec, as the company involved. The notice was first published and last updated on the same day, September 28, 2026.

Quick Facts

• Product: PMS-FAMPRIDINE 10 mg tablet
• Company: Pharmascience Inc.
• Market authorization: DIN 02496216
• Affected lot: 24123884
• Recall class: Type II
• Recall number: RA-82684
• Depth of recall: Retailers
• Issue: Affected lot may contain foreign material particles

Products Affected by This Recall

Only one product is named in the notice: PMS-FAMPRIDINE, sold as a 10 mg tablet under Drug Identification Number (DIN) 02496216. The single lot involved is 24123884.

No other strengths, dosage forms or lot numbers are listed. Patients and pharmacies should compare the lot number printed on their packaging with the one above to confirm whether their product is part of the recall.

What Triggered the Recall

The stated reason is short and specific: the affected lot may contain foreign material particles. Health Canada files this under contamination of a health product. The notice does not identify what the particles are, where in the process they may have entered the product, or how the problem was found.

The notice also does not describe any reported injuries or adverse reactions linked to the lot. Because the wording says the lot may contain particles, the recall appears to be a precaution covering the whole batch rather than a confirmation that every tablet is affected.

Areas and Consumers Impacted

The affected lot was distributed in the following provinces:

• Alberta
• British Columbia
• Manitoba
• New Brunswick
• Newfoundland and Labrador
• Ontario
• Quebec

Anyone in these provinces who has been dispensed PMS-FAMPRIDINE 10 mg tablets should check the lot number on the bottle or package. Because the recall reaches the retail level, pharmacies and other retailers that received the lot are also part of the response.

Steps Consumers Should Take

Health Canada lays out a short list of actions for anyone who may have the product:

• Verify your product. Check whether your PMS-FAMPRIDINE 10 mg tablets carry lot number 24123884.
• Talk to a healthcare provider first. Consult your healthcare provider before discontinuing use of the affected product, or if you have any health concerns.
• Contact the recalling firm. If you have questions about the recall, get in touch with Pharmascience Inc.
• Report side effects. Report any health product related side effects to Health Canada.
• Report other complaints. Any other health product safety complaints can also be reported to Health Canada.

The guidance to speak with a healthcare provider before stopping the medication matters. The notice does not tell patients to stop taking the product on their own, so anyone with the affected lot should seek professional advice on how to proceed.

From the Agency

Health Canada’s notice says the affected lot may contain foreign material particles and directs consumers to consult a healthcare provider before discontinuing use of the affected product, or for any health concerns. The notice describes the recall as health product contamination and gives the recalling firm as Pharmascience Inc. of Montreal.

The recall was published on September 28, 2026, and the notice remains available on the Government of Canada recalls website. Canadians can also subscribe there to receive emails about new and updated recalls and safety alerts. Health Canada notes that its portal accepts reports of health or safety concerns, which helps the regulator monitor the safety of products on the Canadian market.

Anyone who is unsure whether their medication is affected should ask their pharmacist or prescriber to check the lot number against recall RA-82684.